Destruction of dopaminergic neurons in the midbrain by 6-hydroxydopamine decreases hippocampal cell proliferation in rats: Reversal by fluoxetine

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Suzuki, Katsuaki ^a   Okada, Kyoko ^a   Wakuda, Tomoyasu ^a   Shinmura, Chie ^a   Kameno, Yosuke ^a   Iwata, Keiko ^a   Takahashi, Taro ^a   Suda, Shiro ^a   Matsuzaki, Hideo ^b   Iwata, Yasuhide ^a   Hashimoto, Kenji ^c   Mori, Norio ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; MAPROTILINE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE; ADRENERGIC RECEPTOR STIMULATING AGENT; DOPAMINE; GLIAL FIBRILLARY ACIDIC PROTEIN; SEROTONIN UPTAKE INHIBITOR;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CELL PROLIFERATION; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; HIPPOCAMPUS; IMMUNOREACTIVITY; MESENCEPHALON; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; RAT; SUBSTANTIA NIGRA; SUBVENTRICULAR ZONE; VENTRAL TEGMENTUM; ANIMAL; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOLOGY; DRUG EFFECT; HUMAN; IMMUNOHISTOCHEMISTRY; MAZE TEST; METABOLISM; MOTOR ACTIVITY; NERVE CELL; SPRAGUE DAWLEY RAT;

RATTUS;

ADRENERGIC AGENTS; ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DOPAMINE; FLUOXETINE; GLIAL FIBRILLARY ACIDIC PROTEIN; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; MAZE LEARNING; MESENCEPHALON; MOTOR ACTIVITY; NEURONS; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN UPTAKE INHIBITORS; TYROSINE 3-MONOOXYGENASE;

EID: 77949535527     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009260     Document Type: Article

References (48)

1. Samii A, Nutt JG, Ransom BR (2004) Parkinson's disease. Lancet 363: 1783-1793.
2. Schrag A, Achott M (2006) Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 5: 355-363.
3. Weintraub D, Comella CL, Horn S (2008) Parkinson's disease - Part 1: Pathophysiology, symptoms, burden, diagnosis, and assessment. Am J Mnag Care 14: S40-S48.
4. Berendse HW, Booij J, Francot CM, Bergmans PL, Hijman R, et al. (2001) Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann Neurol 50: 34-41.
5. Oertel WH, Höglinger GU, Caraceni T, Girotti F, Eichhorn T, et al. (2001) Depression in Parkinson's disease. An update. Adv Neurol 86: 373-383.
6. Brandstädter D, Oertel WH (2003) Depression in Parkinson's disease. Adv Neurol 91: 371-381.
7. Schrag A (2006) Quality of life and depression in Parkinson's disease. J Neurol Sci 248: 151-157.
8. Ishihara L, Brayne C (2006) A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand 113: 211-220.
9. Chaudhuri KR, Healy DG, Schapira AH, National Institute for Clinical Excellence (2006) Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 5: 235-245.
10. Schrag A, Barone P, Brown RG, Leentjens AF, McDonald WM, et al. (2007) Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord 22: 1077-1092.
11. Weintraub D, Comella CL, Horn S (2008) Parkinson's disease - Part III: Neuropsychiatric symptoms. Am J Manag Care 14: S59-S69.
12. Lemke MR (2008) Depressive symptoms in Parkinson's disease. Eur J Neurol 15 (Suppl 1): 21-25.
13. Gonera EG, van't Hof M, Berger HJ, van Weel C, Horstink MW (1997) Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord 12: 871-876.
14. Reijnders JSAM, Ehrt U, Weber WEJ, Aarsland D, Leestjens AFG (2008) A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 23: 183-189.
15. Dell'Agnello G, Ceravolo R, Nuti A, Bellini G, Piccinni A, et al. (2001) SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol 24: 221-227.
16. Vajda FJ, Solinas C (2005) Current approaches to management of depression in Parkinson's disease. J Clin Neurosci 12: 739-743.
17. Weintraub D, Taraborelli D, Morales KH, Duda JE, Katz IR, et al. (2006) Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study. J Neuropsychiatry Clin Neurosci 18: 377-383.
18. Devos D, Dujardin K, Poirot I, Moreau C, Cottencin O, et al. (2008) Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 23: 850-857.
19. Duman RS, Nakagawa S, Malberg J (2001) Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 25: 836-844.
20. Hashimoto K, Shimizu E, Iyo M (2004) Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 45: 104-114.
21. Sapolsky RM (2004) Is impaired neurogenesis relevant to the affective symptoms of depression? Biol Psychiatry 56: 137-139.
22. Dranovsky A, Hen R (2006) Hippocampal neurogenesis: regulation by stress and antidepressants. Biol Psychiatry 59: 1136-1143.
23. Sahay A, Hen R (2007) Adult hippocampal neurogenesis in depression. Nat Neurosci 10: 1110-1115.
24. Zhao C, Deng W, Gage FH (2008) Mechanisms and functional implications of adult neurogenesis. Cell 132: 645-660.
25. Perera TD, Park S, Nemirovskaya Y (2008) Cognitive role of neurogenesis in depression and antidepressant treatment. Neuroscientist 14: 326-338.
26. Baker SA, Baker KA, Hagg T (2004) Dopaminergic nigrostriatal projections regulate neural precursor proliferation in the adult mouse subventricular zone. Eur J Neurosci 20: 575-579.
27. Freundlieb N, François C, Tandé D, Oertel WH, Hirsch EC, et al. (2006) Dopaminergic substantia nigra neurons project topographically organized to the subventricular zone and stimulate precursor cell proliferation in aged primates. J Neurosci 26: 2321-2325.
28. Höglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, et al. (2004) Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 7: 726-735.
29. Winner B, Geyer M, Couillard-Despres S, Aigner R, Bogdahn U, et al. (2006) Striatal deafferentation increases dopaminergic neurogenesis in the adult olfactory bulb. Exp Neurol 197: 113-121.
30. Borta A, Höglinger GU (2007) Dopamine and adult neurogenesis. J Neurochem 100: 587-595.
31. Scatton B, Simon H, Le Moal M, Bischoff S (1980) Origin of dopaminergic innervation of the rat hippocampal formation. Neurosci Lett 18: 125-131.
32. Amalric M, Koob GF (1993) Functionally selective neurochemical afferents and efferents of the mesocorticolimbic and nigrostriatal dopamine system. Prog Brain Res 99: 209-226.
33. Gasbarri A, Sulli A, Packard MG (1997) The dopaminergic mesencephalic projections to the hippocampal formation in the rat. Prog Neuropsychopharmacol Biol psychiatry 21: 1-22.
34. Coronas V, Bantubungi K, Fombonne J, Krantic S, Schiffmann SN, et al. (2004) Dopamine D3 receptor stimulation promotes the proliferation of cells derived from the post-natal subventricular zone. J Neurochem 91: 1292-1301.
35. 2 receptor stimulation promotes the proliferation of neural progenitor cells in adult mouse hippocampus. Neuroreport 18: 659-664.
36. Malberg JE, Duman RS (2003) Cell proliferation in adult hippocampus is decreased by inescapable stress: reversal by fluoxetine treatment. Neuropsychopharmacology 28: 1562-1571.
37. Beauquis J, Roig P, Homo-Delarche F, De Nicola A, Saravia F (2006) Reduced hippocampal neurogenesis and number of hilar neurones in streptozotocininduced diabetic mice: reversion by antidepressant treatment. Eur J Neurosci 23: 1539-1546.
38. Malberg JE, Eisch AJ, Nestler EJ, Duman RS (2000) Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 20: 9104-9110.
39. Manev H, Uz T, Smalheiser NR, Manev R (2001) Antidepressants alter cell proliferation in the adult brain in vivo and in neural cultures in vitro. Eur J Pharmacol 411: 67-70.
40. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, et al. (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301: 805-809.
41. Kodama M, Fujioka T, Duman RS (2004) Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 56: 570-580.
42. Grote HE, Bull ND, Howard ML, van Dellen A, Blakemore C, et al. (2005) Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur J Neurosci 22: 2081-2088.
43. Loughlin SE, Fallon JH (1985) Locus coeruleus. In: Paxinos G, ed (1985) The rat nervous system. Volume 2, Academic Press Australia. pp 79-93.
44. Gesi M, Soldani P, Giorgi FS, Santinami A, Bonaccorsi I, et al. (2000) The role of the locus coeruleus in the development of Parkinson's disease. Neurosci Biobehav Rev 24: 655-668.
45. Forno LS (1996) Neuropathology of Parkinson's Disease. J Neuropathol Exp Neurol 55: 259-272.
46. Greenfield JG, Bosanquet FD (1953) The brain-stem lesions in Parkinsonism. J Neurol Neurosurg Psychiatry 16: 213-226.
47. Ehringer H, Hornykiewicz O (1960) Verteilung von noradrenalin und dopamine (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems. Klin Wschr 38: 1236-1239.
48. Wakuda T, Matsuzaki H, Suzuki K, Iwata Y, Shinmura C, et al. (2008) Perinatal asphyxia reduces dentate granule cells and exacerbates methamphetamine-induced hyperlocomotion in adulthood. PLoS ONE 3: e3648.